Speciality pharmaceutical company Prosonix has began the PSX1002 Phase 2 study in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Designed by Prosonix based on its particle engineering technology platform, the Psx1002 is an orally inhaled novel drug-only formulation of glycopyrronium bromide.
Go deeper with GlobalData
Prosonix chief medical officer Dr Geoff Down said that glycopyrronium bromide was likely to be useful in reversing airway constriction in COPD patients, increasing airflow, relieving symptoms and improving quality of life.
The randomised, double-blind study is designed to assess the efficacy of PSX1002 on lung function, tolerability and safety of a range of doses compared to placebo, delivered through pressurised metered dose inhaler (pMDI) in COPD patients.
A total of 40 patients are expected to be enrolled in the study, while dosing of initial two groups of eight patients was carried at the Medicines Evaluation Unit in Manchester, UK.
See Also:
Improved lung function as measured by forced expiratory volume in one second (FEV1) area under the curve from time zero to 24 hours post dose is the primary endpoint.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe study will also assess several physiological (lung function) and pharmacokinetic endpoints.
Prosonix CEO David Hipkiss said the trial was the first ever clinical study of a drug formulation that the company completely created and developed in-house using the particle engineering technology and respiratory medicine by design approach.
"This important milestone, along with the planned EU filing of our lead product PSX1001 in the first half of 2014, highlights the rapid progress that Prosonix is making, and the significant value we are generating for all our stakeholders who have backed our respiratory focused strategy in mono and combination products," Hipkiss said.
The company expects to release the results in early 2014.
Image: A chest X-ray demonstrating severe COPD. Photo: courtesy of James Heilman, MD.
